Episode Appearances
Pivot · Jun 2, 2026
Anthropic's IPO, Platner's Campaign Controversies, and Blue Origin's Setback
“Eli Lilly CEO interviewed by Kara Swisher; discussed GLP-1 drug strategy and pharmaceutical innovation”
Campaign Crisis Communication StrategyAnthropic IPO and AI Startup ValuationsPolitical Candidate Personal Conduct Standards
View Analysis
BioSpace · May 13, 2026
Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay
“Highest paid pharma CEO in 2025 at $36.7M; face of GLP-1 market; conducting media victory lap”
FDA Commissioner leadership transition and removalRegulatory uncertainty and HHS agency turnoverCommissioner's National Priority Review voucher program
View Analysis